CVS CVS HEALTH Corp

NYSE cvshealth.com


$ 78.23 $ 1.46 (1.9 %)    

Friday, 31-Oct-2025 19:54:03 EDT
QQQ $ 629.16 $ 3.02 (0.48 %)
DIA $ 475.58 $ 0.66 (0.14 %)
SPY $ 681.80 $ 2.23 (0.33 %)
TLT $ 90.21 $ -0.27 (-0.3 %)
GLD $ 368.20 $ -2.01 (-0.54 %)
$ 78.15
$ 76.69
$ 77.90 x 10
$ 78.26 x 250
$ 76.12 - $ 78.23
$ 41.77 - $ 85.15
9,680,843
na
99.21B
$ 0.65
$ 211.53
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-29-2025 09-30-2025 10-Q
2 07-31-2025 06-30-2025 10-Q
3 05-01-2025 03-31-2025 10-Q
4 02-12-2025 12-31-2024 10-K
5 11-06-2024 09-30-2024 10-Q
6 08-07-2024 06-30-2024 10-Q
7 05-01-2024 03-31-2024 10-Q
8 02-07-2024 12-31-2023 10-K
9 11-01-2023 09-30-2023 10-Q
10 08-02-2023 06-30-2023 10-Q
11 05-03-2023 03-31-2023 10-Q
12 02-08-2023 12-31-2022 10-K
13 11-02-2022 09-30-2022 10-Q
14 08-03-2022 06-30-2022 10-Q
15 05-04-2022 03-31-2022 10-Q
16 02-09-2022 12-31-2021 10-K
17 11-03-2021 09-30-2021 10-Q
18 08-04-2021 06-30-2021 10-Q
19 05-04-2021 03-31-2021 10-Q
20 02-16-2021 12-31-2020 10-K
21 11-06-2020 09-30-2020 10-Q
22 08-05-2020 06-30-2020 10-Q
23 05-06-2020 03-31-2020 10-Q
24 02-18-2020 12-31-2019 10-K
25 11-06-2019 09-30-2019 10-Q
26 08-07-2019 06-30-2019 10-Q
27 05-01-2019 03-31-2019 10-Q
28 02-28-2019 12-31-2018 10-K
29 11-06-2018 09-30-2018 10-Q
30 08-08-2018 06-30-2018 10-Q
31 05-02-2018 03-31-2018 10-Q
32 02-14-2018 12-31-2017 10-K
33 11-06-2017 09-30-2017 10-Q
34 08-08-2017 06-30-2017 10-Q
35 05-02-2017 03-31-2017 10-Q
36 02-09-2017 12-31-2016 10-K
37 11-08-2016 09-30-2016 10-Q
38 08-02-2016 06-30-2016 10-Q
39 05-03-2016 03-31-2016 10-Q
40 02-09-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 evercore-isi-group-maintains-outperform-on-cvs-health-raises-price-target-to-95

Evercore ISI Group analyst Elizabeth Anderson maintains CVS Health (NYSE:CVS) with a Outperform and raises the price target ...

 rbc-capital-maintains-outperform-on-cvs-health-raises-price-target-to-93

RBC Capital analyst Ben Hendrix maintains CVS Health (NYSE:CVS) with a Outperform and raises the price target from $81 to $93.

 cantor-fitzgerald-maintains-overweight-on-cvs-health-raises-price-target-to-95

Cantor Fitzgerald analyst Sarah James maintains CVS Health (NYSE:CVS) with a Overweight and raises the price target from $78...

 truist-securities-reiterates-buy-on-cvs-health-raises-price-target-to-95

Truist Securities analyst David Macdonald reiterates CVS Health (NYSE:CVS) with a Buy and raises the price target from $92 t...

 sp-500-tops-6900-ahead-fed-rate-move-gold-reclaims-4000-whats-moving-markets-wednesday

A powerful surge in AI-related stocks — led by a 9% advance in NVIDIA Corp. (NASDAQ:NVDA) over the past two sessions — propelle...

 cvs-health-delivers-confident-outlook-after-q3-performance-stock-hits-52-week-high

CVS Health topped Q3 estimates with $102.9 billion in revenue and raised its 2025 EPS outlook to up to $6.65 amid strong segmen...

 cvs-health-lowers-fy2025-gaap-eps-guidance-from-384-394-to-034-024-vs-396-est

CVS Health (NYSE:CVS) lowers FY2025 GAAP EPS guidance from $3.84-$3.94 to $(0.34)-$(0.24) vs $3.96 analyst estimate..

 cvs-health-raises-fy2025-adj-eps-guidance-from-630-640-to-655-665-vs-638-est

CVS Health (NYSE:CVS) raises FY2025 Adj EPS guidance from $6.30-$6.40 to $6.55-$6.65 vs $6.38 analyst estimate..

 cvs-health-q3-adj-eps-160-beats-137-estimate-sales-102871b-beat-98849b-estimate

CVS Health (NYSE:CVS) reported quarterly earnings of $1.60 per share which beat the analyst consensus estimate of $1.37 by 16.8...

 inflation-vs-reality-bilello-slams-clearly-wrong-government-data-claiming-health-insurance-prices-fell-18costs-only-go-in-one-direction

Charlie Bilello slams "absurd" gov't data claiming health insurance fell 18%. He says costs "only go in one dir...

 ubs-maintains-buy-on-cvs-health-raises-price-target-to-96

UBS analyst Kevin Caliendo maintains CVS Health (NYSE:CVS) with a Buy and raises the price target from $79 to $96.

 emd-serono-cvs-health-to-partner-on-trumprx-fertility-program-launching-in-2026

Trump and EMD Serono strike a deal to cut fertility drug costs, expand U.S. manufacturing, and launch the TrumpRx Fertility pro...

 cvs-health-helps-improve-access-to-more-affordable-fertility-treatments-trumprx-fertility-program-to-launch-in-january-2026-cvs-specialty-pharmacy-partners-in-trumprx-fertility-program

CVS Specialty Pharmacy will be a core partner in the TrumpRx Fertility program. As the Trump Administration continues to establ...

 morgan-stanley-maintains-overweight-on-cvs-health-raises-price-target-to-89

Morgan Stanley analyst Erin Wright maintains CVS Health (NYSE:CVS) with a Overweight and raises the price target from $82 to...

 goldman-sachs-initiates-coverage-on-cvs-health-with-buy-rating-announces-price-target-of-91

Goldman Sachs analyst Scott Fidel initiates coverage on CVS Health (NYSE:CVS) with a Buy rating and announces Price Target ...

 stocks-tumble-as-trump-mulls-massive-china-tariffs-whats-moving-markets-friday

The stock market stumbled Friday after President Donald Trump threatened a sweeping increase in tariffs on Chinese imports, sen...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION